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Background: Therelationshipbetweenthe severity ofobstructive sleepapnea (OSA)and impaired
glucose metabolism (IGM) has not yet been fully elucidated in patients with OSA. Accordingly, we
sought to clarify this relationship in Japanese patients with OSA.
Methods: The study population consisted of 129 Japanese patients with OSA (apnea-hypopnea in-
dex [AHI] 5). A 75-g oral glucose tolerance test was performed in all patients who had not been
diagnosed as diabetesmellitus (DM). IGMwas defined as either diabetes mellitus (DM) or impaired
glucose tolerance (IGT).
Results: IGM was observed in 78 (60.5%) patients: DM in 39 (30.2%) and IGT in 39 (30.2%). The fre-
quency of IGM was significantly different among patients with AHI30, those with 15 AHI< 30,
and those with AHI<15 (72.1%; 53.7%; 35.0%; respectively, pZ 0.001). Univariate logistic regres-
sion analyses showedmale sex, theBMI, the AHI, and the lowest SpO2 to be significantly associated
with IGM. A stepwise multivariate logistic regression analysis showed amale sex and the AHI to be
independently associated with IGM.
Conclusion: IGM was observed in 60.5% of Japanese patients with OSA (AHI 5), and the preva-
lence of IGM increased according to the severity of OSA. Furthermore, the AHI was independently
associated with IGM, thus suggesting that OSA may contribute to the development of IGM.
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Obstructive sleep apnea (OSA) is characterized by repeti-
tive episodes of upper airway collapse during sleep. Pre-
vious studies have shown that OSA is associated with insulin
resistance,1e9 which thus plays an important role in the.
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though some conflicting results exist with regard to this as-
sociation.10,11 There has so far only been one paper12
investigating the exact prevalence of IGM evaluated by
a 75-g oral glucose tolerance test in patients with OSA. In
the study, Meslier et al.12 reported that impaired glucose
tolerance (IGT) and diabetes mellitus (DM) were observed
in 20.0% of and 30.1% of 494 French men with OSA (ap-
nea-hypopnea index [AHI] 10), respectively. However,
the relationship between the severity of OSA and IGM has
not yet been fully elucidated in patients with OSA. In this
study, we examined this relationship in Japanese patients
with OSA.Materials and methods
Patients
Between April 2006 and September 2007, there were 137
consecutive Japanese patients who underwent overnight
polysomnography for clinically suspected OSA at our hospi-
tals and who did not meet the following exclusion criteria.
The exclusion criteria were signs or symptoms of congestive
heart failure, left ventricular ejection fraction <55%, pre-
vious cerebrovascular diseases, neurological diseases, or
chronic respiratory diseases. Of 137 patients, eight patients
had the AHI <5. Finally, 129 patients (110 men and 19
women, median age of 63 years) who were diagnosed to
have OSA (AHI 5) were analyzed. No patients with type 1
DM were included in the present study. The patients were
divided into the following three groups based on the AHI:
patients with AHI 30 (group A, nZ 68), those with
15 AHI < 30 (group B, nZ 41), and those with AHI <15
(group C, nZ 20). Hypertension was defined as systolic
blood pressure 140 mmHg and/or diastolic blood pressure
90 mmHg. Dyslipidemia was defined as serum low-density
lipoprotein cholesterol level 3.6 mmol/l [140 mg/dl],
high-density lipoprotein cholesterol level <1.0 mmol/l
[40 mg/dl], or triglyceride level 1.7 mmol/l [150 mg/dl].
Coronary artery disease was defined as luminal diameter
stenosis of 75% in at least one of the coronary arteries
on coronary angiography, previous myocardial infarction,
previous coronary revascularization therapy, or vasospastic
angina pectoris confirmed by a methyl-ergonovine or ace-
tylcholine provocation test. The study protocol was ap-
proved by the ethics committee at our institution, and
informed consent was obtained from each patient before
the study.Oral glucose tolerance test
A 75-g oral glucose tolerance test was performed in 102
patients (79.1%) who had not been diagnosed to have
DM. The patients were considered to have DM if they had
a fasting plasma glucose level 7 mmol/l [126 mg/dl] and/
or a plasma glucose level 11.1 mmol/l [200 mg/dl] at 2 h
after the glucose load. IGT was defined as a plasma glucose
level of 7.7 mmol/l [140 mg/dl] and <11.1 mmol/l
[200 mg/dl] at 2 h after the glucose load. IGM was defined
as either DM or IGT.Overnight polysomnography
Overnight polysomnography was performed using a comput-
erized system (E-series, Compumedics, Abbotsford,
Australia). This investigation consisted of monitoring of the
electroencephalogram, electro-oculogram, submental elec-
tromyogram, electrocardiogram, thoraco-abdominal excur-
sions, oronasal airflowby an airflow pressure transducer, and
arterial oxygen saturation (SpO2) by pulse oximetry. The
polysomnographywasmanually evaluatedby anexperienced
physician. Central apnea was defined as an absence of oro-
nasal airflow during sleep for 10 s associated with absent
respiratory effort. An obstructive apnea was defined as an
absence of oronasal airflow for 10 s in the presence of
out-of-phase thoraco-abdominal effort. A hypopnea was de-
fined as a50% reduction in oronasal airflow for10 s, asso-
ciated with a3% fall in SpO2. The AHI was calculated as the
mean number of apneas and hypopneas per hour of sleep. In
addition, the central or obstructive apnea index was calcu-
lated as the mean number of central or obstructive apneas,
respectively. As obstructive hypopneas can not be easily dis-
tinguished from central hypopneas, we did not calculate the
central or obstructive hypopnea index.
Statistical analysis
Continuous data are expressed as mean SD or median (first
to third quartiles), and categorical data are expressed as
number (%).Comparisonsofcategorical dataamongthe three
groupswereanalyzedby theFisher’s exactor chi-square test.
One-factor analysis of variance with Scheffe’s post hoc test
was used for comparisons of normally distributed continuous
data. When continuous data were not normally distributed,
the Kruskal-Wallis test with the Scheffe’s post hoc test was
used.Univariate andmultivariate logistic regression analyses
were performed to determine the factors associated with
IGM. A p value<0.05 was considered to be statistically signif-
icant. All analyses were performed using the SPSS 12.0J soft-
ware package for Windows (SPSS Inc, Tokyo, Japan).
Results
The patient characteristics are shown in Table 1. The BMI
was significantly greater in group A (27.3 4.1 kg/m2)
than in groups B (25.1 2.9 kg/m2, p< 0.05) and C
(23.7 2.7 kg/m2, p< 0.05). There were no significant
differences in age, body height, gender, frequency of hy-
pertension, hyperlipidemia, current smoking, or coronary
artery disease, and medications, such as antihypertensive
drugs and statins, among the three groups.
The overnight polysomnographic findings are shown in
Table 2. The total sleep time was significantly shorter in
group A (369 110 min) than in group C (446 108 min,
p< 0.05). The obstructive apnea index, central apnea index,
and total time of SpO2 < 90% were significantly greater in
group A than in groups B (p< 0.05) and C (p< 0.05). The low-
est SpO2 was significantly lower in group A than in groups B
(p< 0.05) and C (p< 0.05).
Fig. 1 shows the prevalence of IGM among the three
groups. IGM was observed in 78 (60.5%) patients: DM in 39
(30.2%) and IGT in 39 (30.2%). The prevalence of IGM
Table 1 Patient characteristics.
Variables Group A
(nZ 68)
Group B
(nZ 41)
Group C
(nZ 20)
Age, yrs 63.5
(50.0e72.8)
68.0
(56.0e73.0)
54.5
(37.3e69.0)
Men 62 (91.2) 33 (80.5) 15 (75)
Body height, cm 166 6.8 163 9.8 163 9.7
BMI, kg/m2 27.3 4.1* 25.1 2.9 23.7 2.7
Hypertension 50 (73.5) 34 (82.9) 12 (60)
Dyslipidemia 49 (72.1) 30 (73.2) 12 (60)
Current smoker 15 (22.1) 10 (24.4) 4 (20)
Coronary artery
disease
10 (14.7) 14 (34.1) 3 (15)
Medications
Diuretics 7 (10.2) 6 (14.6) 3 (15)
Ca antagonists 37 (53.6) 24 (34.8) 8 (11.6)
a blockers 8 (11.8) 4 (9.8) 2 (10)
b blockers 11 (16.2) 15 (36.6) 5 (25)
ACEI/ARB 31 (45.6) 22 (53.7) 6 (30)
Statins 19 (27.9) 15 (36.6) 3 (15)
Data are presented as the means  SD, medians (first to third
quartiles) or No. (%).
BMIZ body mass index; ACEIZ angiotensin-converting enzyme
inhibitors; ARBZ angiotensin II type 1 receptor blockers.
Group A Z patients with AHI 30; group B Z those with 15 
AHI <30; group C Z those with AHI <15.
*p< 0.05 vs. groups B and C.
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Figure 1 The prevalence of impaired glucose metabolism.
Group AZ patients with AHI 30; group BZ those with
15 AHI < 30; group CZ those with AHI <15; IGT Z impaired
glucose tolerance; DM Z diabetes mellitus; pZ 0.001 among
the three groups.
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72.1%; group B, 53.7%; group C, 35.0%; pZ 0.001).
Univariate logistic regression analyses showed a male
sex, the BMI, AHI, and the lowest SpO2 to be significantly as-
sociated with IGM (Table 3). Table 4 shows the results of
a multivariate logistic regression analysis performed to de-
termine independent factors of IGM. Since the lowest SpO2Table 2 Overnight polysomnographic findings.
Variables Group A
(nZ 68)
Group B
(nZ 41)
Group C
(nZ 20)
Sleep period
time, min
55580 53595 546103
Total sleep
time, min
369110** 401101 446108
AHI 53.8
(41.9e65.3)*
22.1
(18.7e25.2)**
8.4
(7.0e11.8)
Obstructive
apnea index
18.5
(11.0e37.9)*
3.7
(2.1e7.2)
0.8
(0.03e2.3)
Central apnea
index
0.9
(0.0e3.0)*
0.2
(0.0e0.7)
0.0
(0.0e0.2)
Lowest SpO2, % 77.47.8* 84.65.2 88.74.0
Total time
of SpO2 <90%
during sleep,
min
19.2
(5.7e46.9)*
1.9
(0.3e7.4)
0.05
(0.0e1.0)
Data are presented as the means  SD or medians (first to third
quartiles).
AHIZapnea-hypopnea index; SpO2Zarterial oxygen saturation.
*p< 0.05 vs. groups B and C, **p< 0.05 vs. group C.correlated strongly with the AHI (rZ 0.77, p< 0.001), the
lowest SpO2 was not included in this analysis. A multivariate
logistic regression analysis showed a male sex and the AHI
to be independently associated with IGM (odds ratio 4.48
[95% CI 1.44e13.9] and odds ratio 1.03 [95% CI 1.01e
1.05], respectively) (Table 4). When the lowest SpO2 was
used as an independent variable instead of the AHI, a multi-
variate logistic regression analysis showed a male sex and
the lowest SpO2 were independently associated with IGM
(odds ratio 6.45 [95% CI 1.96e21.5] and odds ratio 0.91
[95% CI 0.85e0.96], respectively).
Discussion
In the present study, IGM was observed in 60.5% of Japanese
patients with OSA (AHI 5). This prevalence is obviouslyTable 3 Univariate logistic regression analysis to deter-
mine factors related to IGM.
Variables Odds (95% CI) p
value
Age, yrs 1.01 (0.99e1.04) 0.39
Male (0Z no, 1Z yes) 5.52 (1.85e16.5) 0.002
BMI, kg/m2 1.16 (1.04e1.29) 0.009
Hypertension (0Z no, 1Z yes) 1.64 (0.74e3.65) 0.23
Dyslipidemia (0Z no, 1Z yes) 1.84 (0.86e3.97) 0.12
Current smoker (0Z no, 1Z yes) 1.09 (0.47e2.55) 0.84
Coronary artery disease
(0Z no, 1Z yes)
0.94 (0.40e2.23) 0.89
AHI 1.03 (1.01e1.05) 0.001
Lowest SpO2, % 0.92 (0.87e0.97) 0.04
Time of SpO2 <90%, min 1.01 (0.99e1.02) 0.08
Diuretics (0Z no, 1Z yes) 0.61 (0.22e1.76) 0.36
Ca antagonists (0Z no, 1Z yes) 1.04 (0.51e2.10) 0.92
a blocker (0Z no, 1Z yes) 1.73 (0.51e5.84) 0.38
b blockers (0Z no, 1Z yes) 1.25 (0.52e2.90) 0.60
ACEI/ARB (0Z no, 1Z yes) 1.40 (0.68e2.86) 0.36
Abbreviations are the same as in Tables 1 and 2.
CI Z confidence interval.
Table 4 Stepwise multivariate logistic regression analysis
to determine the independent factors related to IGM.
Variables Odds (95% CI) p value
Male (0Z no, 1Z yes) 4.48 (1.44e13.9) 0.01
AHI 1.03 (1.01e1.05) 0.003
Abbreviations are the same as in Tables 1e3.
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population of Japanese adults: a large-population study
reported that the prevalence of IGM evaluated by a 75-g
oral tolerance test was 20.4% in 2,534 Japanese aged >40
years.13 Meslier et al.12 reported IGM to be observed in
50.1% of 494 French men with OSA (AHI 10). In the present
study, the prevalence of IGM was 69% in 100 men with an
AHI 10. This prevalence is significantly higher than the
prevalence of IGM (p< 0.001) in the study by Meslier
et al.12 This difference might be due to patient selection.
In the present study, of 100 men with an AHI 10, 62
(62%) had severe OSA (AHI 30). On the other hand, in
the study of Meslier et al., the prevalence of severe OSA
was 52.8% of 494 men with an AHI 10. Since the present
study indicates that the AHI is an independent factor for
IGM, the high prevalence of IGM in the present study is
likely to contribute, at least partly, to the high prevalence
of severe OSA. Alternatively, there might be a stronger as-
sociation of OSA with IGM in Japanese patients with OSA
than in Caucasian patients with OSA.
Since IGM is a well-established risk factor for future
cardiovascular diseases,13e17 a high prevalence of IGM in
patients with OSA and a significant association between
the severity of OSA and IGM may therefore, at least partly,
explain why patients with OSA are at high risk for cardiovas-
cular events.18e25
Although our study naturally cannot clarify the causality
between OSA and IGM, there are several lines of evidence
that support a causal relationship between the both. First,
the activation of the sympathetic nervous system, which is
observed in patients with OSA,26e30 could impair glucose
homeostasis by increasing glycogen breakdown and gluco-
neogenesis. Second, sleep loss and sleep deprivation ac-
companied by OSA could cause IGM through the activation
of the sympathetic nervous system as well as the activation
of the hypothalamic-pituitary-adrenal axis.31e33 Third, re-
current intermittent hypoxia caused by OSA could directly
cause IGM.34e38 Experimental data in humans have shown
that exposure to high altitude or hypobaric hypoxia acutely
impairs insulin sensitivity.36,38 OSA-associated hypoxia and
hypoxia/reoxygenation increases the production of reac-
tive oxygen species and also activates redox-sensitive tran-
scription factors including nuclear factor kappa B, thus
resulting in an increased production/release of tumor ne-
crosis factor-a,39,40 which thus plays an important role in
the development of insulin resistance.41,42 In the present
study, the lowest SpO2 also was independently associated
with IGM. This result supports that hypoxia caused by OSA
could contribute to the development of IGM. Fourth, obe-
sity, a major risk factor for IGM as well as OSA, may also
contribute to the high prevalence of IGM in patients with
OSA, although the multivariate logistic regression analysis
did not identify the BMI as an independent factor for IGMin the present study. Since the BMI is lower in Japanese pa-
tients with OSA than in Caucasian patients with OSA,43 the
result may not apply to Caucasian patients with OSA.
The present study has a few certain limitations. First, the
sample size of the present study was relatively small.
Therefore, further studies with a larger population are
needed to confirm our results. Second, it cannot be perfectly
denied that the high prevalence of IGM in the present study
might be due to the selection bias. In addition, in the present
study, there were several exclusion criteria, and the fre-
quencies of hypertension and dyslipidemia were fairly
higher. Therefore, the prevalence of IGM in the present
study may not represent that in the general Japanese
population with OSA. Third, the present study included
patients who were treated with diuretics, angiotensin-
converting enzyme inhibitors, angiotensin receptor
blockers, a blockers, and b blockers, all of which could
possibly affect the glucose metabolism. However, a multi-
variate logistic regression analysis did not identify these
drugs as independent factors for IGM.
In conclusion, IGM was observed in 60.5% of Japanese
patients with OSA (AHI 5), and the prevalence of IGM was
found to increase according to the severity of OSA.
Furthermore, the AHI was independently associated with
IGM, thus suggesting that OSA may contribute to the
development of IGM.
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